Bayer (Germany)

Believe it or not: how much can we rely on published data on potential drug targets?

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patient...

Scientific importance, properties and growing applications of poly(3,4-ethylenedioxythiophene)

This article summarises the industrial applications of poly-(3,4-ethylenedioxythiophene) (PEDT, PEDOT). The basic chemical and physical properties of PEDT are discussed to outli...

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894.)

Treatment of the outlying charge in continuum solvation models

Continuum solvation models have proven to yield very valuable information about solvation effects, if cavities close to the van der Waals surface of the solutes are used for the...

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Predicting drug metabolism: experiment and/or computation?

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in health...

Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments